Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J, He K, Cai L, Chen YC, Yang Y, Shi Q, Woolf TF, Ge W, Guo L, Borlak J, Tong W.
Chem Biol Interact. 2016 Aug 5;255:45-54. doi: 10.1016/j.cbi.2016.03.019. Epub 2016 Mar 19.
Similar articles
In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
Cheng Y, Woolf TF, Gan J, He K.
Chem Biol Interact. 2016 Aug 5;255:23-30. doi: 10.1016/j.cbi.2015.11.029. Epub 2015 Dec 10. Review.
Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury.
He K, Cai L, Shi Q, Liu H, Woolf TF.
Chem Res Toxicol. 2015 Oct 19;28(10):1987-90. doi: 10.1021/acs.chemrestox.5b00201. Epub 2015 Sep 15.
Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, Woolf TF.
Drug Metab Dispos. 2004 Jun;32(6):639-46.
Incorporation of an oxygen from water into troglitazone quinone by cytochrome P450 and myeloperoxidase.
He K, Talaat RE, Woolf TF.
Drug Metab Dispos. 2004 Apr;32(4):442-6.
Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction.
He K, Woolf TF, Kindt EK, Fielder AE, Talaat RE.
Biochem Pharmacol. 2001 Jul 15;62(2):191-8.
Metabolism and excretion of atorvastatin in rats and dogs.
Black AE, Hayes RN, Roth BD, Woo P, Woolf TF.
Drug Metab Dispos. 1999 Aug;27(8):916-23.
Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K, Woolf TF, Hollenberg PF.
J Pharmacol Exp Ther. 1999 Feb;288(2):791-7.
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.
Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang BK, Foster NL, Brown RR, Watkins PB.
Br J Clin Pharmacol. 1998 Sep;46(3):221-8.
Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Black AE, Sinz MW, Hayes RN, Woolf TF.
Drug Metab Dispos. 1998 Aug;26(8):755-63.
Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice.
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF.
Chem Res Toxicol. 1998 Apr;11(4):252-9.
Characterization of the induction of rat microsomal cytochrome P450 by tacrine.
Sinz MW, Woolf TF.
Biochem Pharmacol. 1997 Aug 1;54(3):425-7.
Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons.
Pool WF, Reily MD, Bjorge SM, Woolf TF.
Drug Metab Dispos. 1997 May;25(5):590-7.
In vitro and in vivo disposition of 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (CI-976). Identification of a novel five-carbon cleavage metabolite in rats.
Sinz MW, Black AE, Bjorge SM, Holmes A, Trivedi BK, Woolf TF.
Drug Metab Dispos. 1997 Jan;25(1):123-30.
The effect of cytochromes P4501A induction and inhibition on the disposition of the cognition activator tacrine in rat hepatic preparations.
Bezek S, Kukan M, Pool WF, Woolf TF.
Xenobiotica. 1996 Sep;26(9):935-46.
Identification of a 3-hydroxylated tacrine metabolite in rat and man: metabolic profiling implications and pharmacology.
Pool WF, Woolf TF, Reily MD, Caprathe BW, Emmerling MR, Jaen JC.
J Med Chem. 1996 Jul 19;39(15):3014-8.
Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue.
McNally WP, Pool WF, Sinz MW, Dehart P, Ortwine DF, Huang CC, Chang T, Woolf TF.
Drug Metab Dispos. 1996 Jun;24(6):628-33.
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB.
Hepatology. 1996 Jun;23(6):1429-35.
Species variation in the bioactivation of tacrine by hepatic microsomes.
Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK.
Xenobiotica. 1995 Jan;25(1):103-16.
Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: in vitro/in vivo comparisons.
Kukan M, Bezek S, Pool WF, Woolf TF.
Xenobiotica. 1994 Nov;24(11):1107-17.
Stereoselective hydroxylation of tacrine in rats and humans.
Hooper WD, Pool WF, Woolf TF, Gal J.
Drug Metab Dispos. 1994 Sep-Oct;22(5):719-24.
The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.
Spaldin V, Madden S, Pool WF, Woolf TF, Park BK.
Br J Clin Pharmacol. 1994 Jul;38(1):15-22.
Biodisposition studies with the acyl-coenzyme A: cholesterol acyltransferase inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide, CI-976.
Woolf TF, Black A, Shum YY, McNally W, Lee H, Chang T.
Drug Metab Dispos. 1993 Nov-Dec;21(6):1112-8.
Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF 2nd, Schroeder MC, Kunze KL, Trager WF.
Drug Metab Dispos. 1993 Sep-Oct;21(5):874-82.
An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes.
Madden S, Woolf TF, Pool WF, Park BK.
Biochem Pharmacol. 1993 Jul 6;46(1):13-20.
Characterization of nonlinear elimination of the xanthine-related drug ethimizol in 3-methylcholanthrene-induced rat liver by the "parallel-tube" model.
Kukan M, Woolf TF, Melus M, Bezek S.
Drug Metab Dispos. 1993 May-Jun;21(3):547-50. No abstract available.
Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man.
Woolf TF, Black A, Sedman A, Chang T.
Eur J Drug Metab Pharmacokinet. 1992 Jan-Mar;17(1):21-7.
Metabolism of the acyl-CoA:cholesterol acyltransferase inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide in rat and monkey. Omega-/beta-oxidation pathway.
Woolf TF, Bjorge SM, Black AE, Holmes A, Chang T.
Drug Metab Dispos. 1991 May-Jun;19(3):696-702.
Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog.
Wong BK, Woolf TF, Chang T, Whitfield LR.
Drug Metab Dispos. 1990 Nov-Dec;18(6):980-6.
In vitro metabolism of isoxicam by horseradish peroxidase.
Woolf TF, Black A, Chang T.
Xenobiotica. 1989 Dec;19(12):1369-77.
In vivo metabolism of isoxicam in rats, dogs, and monkeys.
Woolf TF, Black A, Hicks JL, Lee H, Huang CC, Chang T.
Drug Metab Dispos. 1989 Nov-Dec;17(6):662-8.
Preparation of diastereomeric beta-d-glucuronides of the bronchodilator procaterol using immobilized rabbit liver microsomal enzymes.
Woolf TF, Chang T.
Eur J Drug Metab Pharmacokinet. 1989 Apr-Jun;14(2):111-6.
Oxicams: metabolic disposition in man and animals.
Woolf TF, Radulovic LL.
Drug Metab Rev. 1989;21(2):255-76. Review. No abstract available.
Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations.
Woolf TF, Adams JD.
Xenobiotica. 1987 Jul;17(7):839-47.
Basic concepts in drug metabolism: Part II.
Jordan RA, Woolf TF.
J Clin Pharmacol. 1987 Feb;27(2):87-90. Review.
Basic concepts in drug metabolism: Part I.
Woolf TF, Jordan RA.
J Clin Pharmacol. 1987 Jan;27(1):15-7. Review. No abstract available.
Derivatization of chiral amines with (S,S)-N-trifluoroacetylproline anhydride for GC estimation of enantiomeric composition.
Adams JD Jr, Woolf TF, Trevor AJ, Williams LR, Castagnoli N Jr.
J Pharm Sci. 1982 Jun;71(6):658-61.
Filters: Manage Filters